MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (?)
Ratings Breakdown: 3 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $18.57 (53.61% upside)

Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2016Bank of AmericaReiterated RatingHold$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016JPMorgan Chase & Co.Reiterated RatingHold$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016RBC CapitalReiterated RatingOutperform$28.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Piper JaffrayReiterated RatingOverweight$23.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016Deutsche BankLower Price TargetBuy$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Jefferies GroupLower Price TargetHold$24.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2015Raymond JamesReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Needham & Company LLCDowngradeBuy -> Hold$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2014S&P Equity ResearchDowngradeBuy -> Neutral$25.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha